CHMP review bolsters Pradaxa's safety profile but strengthens label
This article was originally published in Scrip
The EMA is to update the product information of Boehringer Ingelheim's direct thrombin inhibitor Pradaxa (dabigatran etexilate) to give clearer guidance to doctors and patients on how to reduce and manage the risk of bleeding associated with the anticoagulant.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.